## Kyung-min Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3046419/publications.pdf

Version: 2024-02-01

414414 394421 1,306 64 19 32 citations g-index h-index papers 65 65 65 2115 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Cancer Research, 2019, 79, 1520-1534.	0.9	126
2	Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein) Tj ETQq0 0 0 rgl Cytology. Molecular and Cellular Proteomics, 2018, 17, 1788-1802.	3T /Overlo 3.8	ck 10 Tf 50 7 66
3	Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. Breast Cancer Research and Treatment, 2015, 154, 13-22.	2.5	62
4	The Role of Nicotinamide in Cancer Chemoprevention and Therapy. Biomolecules, 2020, 10, 477.	4.0	60
5	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Medicine, 2022, 20, 105.	5.5	60
6	microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival. Oncotarget, 2017, 8, 32769-32782.	1.8	55
7	Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Human Pathology, 2015, 46, 1027-1035.	2.0	47
8	Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism. PLoS ONE, 2017, 12, e0174126.	2.5	47
9	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumor Biology, 2016, 37, 4743-4753.	1.8	43
10	Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. Radiology, 2016, 278, 356-364.	7.3	42
11	Overexpression of HIF1 $\hat{l}\pm$ and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 183-190.	2.8	38
12	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clinical and Experimental Metastasis, 2016, 33, 179-185.	3.3	36
13	MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case–control study. Breast Cancer Research and Treatment, 2017, 162, 559-569.	2.5	32
14	Automated Gleason Scoring and Tumor Quantification in Prostate Core Needle Biopsy Images Using Deep Neural Networks and Its Comparison with Pathologist-Based Assessment. Cancers, 2019, 11, 1860.	3.7	32
15	Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Science Advances, 2020, 6, eaav7416.	10.3	29
16	Viewing the Eph receptors with a focus on breast cancer heterogeneity. Cancer Letters, 2018, 434, 160-171.	7.2	28
17	A Pilot Study Evaluating Liquid-Based Fine Needle Aspiration Cytology of Breast Lesions: A Cytomorphological Comparison of SurePath® Liquid-Based Preparations and Conventional Smears. Acta Cytologica, 2013, 57, 391-399.	1.3	27
18	Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 563-570.	2.8	23

#	Article	IF	CITATIONS
19	Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. Cells, 2020, 9, 19.	4.1	23
20	Expression of Indoleamine 2,3-Dioxygenase and Infiltration of FOXP3+ Regulatory T Cells Are Associated with Aggressive Features of Papillary Thyroid Microcarcinoma. Thyroid, 2014, 24, 1232-1240.	4.5	21
21	Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Journal of Breast Cancer, 2016, 19, 261.	1.9	21
22	Gene expression profiling of calcifications in breast cancer. Scientific Reports, 2017, 7, 11427.	3.3	21
23	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. Tumor Biology, 2016, 37, 11017-11024.	1.8	20
24	Parallel Reaction Monitoring-Mass Spectrometry (PRM-MS)-Based Targeted Proteomic Surrogates for Intrinsic Subtypes in Breast Cancer: Comparative Analysis with Immunohistochemical Phenotypes. Journal of Proteome Research, 2020, 19, 2643-2653.	3.7	19
25	PHLI-seq: constructing and visualizing cancer genomic maps in 3D by phenotype-based high-throughput laser-aided isolation and sequencing. Genome Biology, 2018, 19, 158.	8.8	18
26	Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer. Scientific Reports, 2017, 7, 3466.	3.3	15
27	Integrated Multiâ€Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basalâ€Like Tripleâ€Negative Breast Cancer. Proteomics - Clinical Applications, 2018, 12, e1700125.	1.6	15
28	Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches. Nature Communications, 2022, 13, 2540.	12.8	15
29	MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiologica, 2017, 58, 792-799.	1.1	14
30	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage l–III breast cancer patients. British Journal of Cancer, 2019, 121, 230-236.	6.4	14
31	Molecular Profiling of Malignant Pleural Effusions with Next Generation Sequencing (NGS): Evidence that Supports Its Role in Cancer Management. Journal of Personalized Medicine, 2020, 10, 206.	2.5	14
32	Imaging Findings of Variable Axillary Mass and Axillary Lymphadenopathy. Ultrasound in Medicine and Biology, 2014, 40, 1934-1948.	1.5	13
33	Feasibility Study of Ultrasonographic Criteria for Microscopic and Macroscopic Extra-Thyroidal Extension Based on Thyroid Capsular Continuity and Tumor Contour in Patients with Papillary Thyroid Carcinomas. Ultrasound in Medicine and Biology, 2016, 42, 2391-2400.	1.5	12
34	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	3.0	12
35	Combined Morphologic and Molecular Classification for Predicting Lymph Node Metastasis in Early-Stage Colorectal Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 1809-1816.	1.5	11
36	Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1574-1584.	6.4	10

3

#	Article	IF	CITATIONS
37	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 233-241.	2.5	10
38	Promoter methylation of cysteine dioxygenase type 1: gene silencing and tumorigenesis in hepatocellular carcinoma. Annals of Hepato-biliary-pancreatic Surgery, 2017, 21, 181.	0.1	10
39	Identification of TUBB2A by quantitative proteomic analysis as a novel biomarker for the prediction of distant metastatic breast cancer. Clinical Proteomics, 2020, 17, 16.	2.1	10
40	Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2021, 25, 207-229.	3.8	10
41	High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy. Journal of Pathology and Translational Medicine, 2018, 52, 369-377.	1.1	10
42	Calsequestrin 2 overexpression in breast cancer increases tumorigenesis and metastasis by modulating the tumor microenvironment. Molecular Oncology, 2022, 16, 466-484.	4.6	10
43	Nicotinamide (niacin) supplement increases lipid metabolism and ROSâ€induced energy disruption in tripleâ€negative breast cancer: potential for drug repositioning as an antiâ€tumor agent. Molecular Oncology, 2022, 16, 1795-1815.	4.6	10
44	Diffusion-weighted Breast MRI in Prediction of Upstaging in Women with Biopsy-proven Ductal Carcinoma in Situ. Radiology, 2022, 305, 307-316.	7.3	10
45	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. Human Pathology, 2015, 46, 246-254.	2.0	9
46	Association of preoperative breast MRI features with locoregional recurrence after breast conservation therapy. Acta Radiologica, 2018, 59, 409-417.	1.1	9
47	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. Breast Cancer Research and Treatment, 2019, 176, 453-460.	2.5	9
48	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 707-714.	2.5	8
49	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 117-127.	2.5	8
50	Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2-metastatic breast cancer Journal of Clinical Oncology, 2021, 39, 1013-1013.	1.6	7
51	Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatmentâ€naà ve patients: A singleâ€center study. Cancer Medicine, 2022, 11, 2193-2203.	2.8	6
52	Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: an independent external validation study. Modern Pathology, 2022, 35, 1449-1457.	5.5	5
53	Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass. Scientific Reports, 2021, 11, 8016.	3.3	4
54	A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. Cancer Research and Treatment, 2021, , .	3.0	4

#	Article	IF	CITATIONS
55	Cytologic Diagnosis of Metastatic Alveolar Rhabdomyosarcoma in Cerebrospinal Fluid: A Case Report. Journal of Pathology and Translational Medicine, 2018, 52, 262-266.	1.1	3
56	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy. Journal of Breast Cancer, 2020, 23, 599.	1.9	3
57	Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Cancer Research, 2022, 82, PD15-08-PD15-08.	0.9	3
58	Novel cytomorphologic characteristics suggesting human papillomavirus infection in patients diagnosed as negative for intraepithelial lesion or malignancy and a comparison of diagnostic performance of three human papillomavirus tests. Diagnostic Cytopathology, 2018, 46, 833-839.	1.0	2
59	Comparison of clinical performance of two high-throughput liquid bead microarray assays, GeneFinder and CareGENE, for cervical screening in the general population. Archives of Virology, 2019, 164, 2699-2706.	2.1	2
60	Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma. Journal of Breast Cancer, 2020, 23, 36.	1.9	1
61	Tyrosine aminoacyl-tRNA synthetase sensitizes breast cancer to chemotherapy through a necroptosis-mediated mechanism Journal of Global Oncology, 2019, 5, 40-40.	0.5	1
62	Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. Cancer Research, 2022, 82, PD2-08-PD2-08.	0.9	1
63	Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. Journal of Translational Medicine, 2021, 19, 7.	4.4	0
64	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer Journal of Clinical Oncology, 2016, 34, e23268-e23268.	1.6	0